Rallybio Corporation (RLYB) Investor Relations Documents

Rallybio Corporation (RLYB) investor relations documents from the company's IR site: 2 presentations, 10 press releases; latest deck 2026-02-19. Read in-app with summaries. First-party data.

Corporate Presentation – February 2026: Rallybio is developing RLYB116, a small protein C5 inhibitor for complement-mediated diseases, targeting a $5B+ market opportunity in immune PTR and APS.

Investor relations documents — source: company IR site

Published	Type	Document
2026-06-01	Press release	Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and
2026-03-02	Press release	Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
2026-02-19	Presentation	Corporate Presentation – February 2026
2026-02-17	Press release	Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal C
2026-02-03	Press release	Rallybio Announces Reverse Stock Split of Common Stock
2025-03-13	Press release	Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
2024-12-02	Presentation	RLYB116 Clinical Program Update – December 2024
2024-03-12	Press release	Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
2022-08-08	Press release	Rallybio Reports Second Quarter 2022 Financial Results
2022-03-15	Press release	Q4 2021 Earnings Release
	Press release	Rallybio Named Innovator of the Month by Senator Chris Murphy (D-Conn)
	Press release	Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer

RLYB overview · RLYB earnings · RLYB financials · RLYB KPIs · RLYB ownership · RLYB peers · RLYB filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.